Details

Autor(en) / Beteiligte

• Hazar, Volkan
• Karasu, Gülsün Tezcan
• Uygun, Vedat
• Özbek, Namık
• Karakükçü, Musa
• Öztürk, Gülyüz
• Daloğlu, Hayriye
• Kılıç, Suar Çakı
• Aksu, Tekin
• Ünal, Ekrem
• Koçak, Ülker
• Yeşilipek, Akif
• Akçay, Arzu
• Gürsel, Orhan
• Küpesiz, Alphan
• Okur, Fatma Visal
• İleri, Talia
• Kansoy, Savaş
• Bayram, İbrahim
• Karagün, Barbaros Şahin
• Gökçe, Müge
• Kaya, Zühre
• Ok Bozkaya, İkbal
• Patıroğlu, Türkan
• Aksoylar, Serap

Titel

Role of a second transplantation for children with acute leukemia following posttransplantation relapse: a study by the Turkish Bone Marrow Transplantation Study Group

Ist Teil von

• Leukemia & lymphoma, 2020-05, Vol.61 (6), p.1465-1474

Ort / Verlag

United States: Taylor & Francis

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• We examined outcomes of 51 pediatric patients with relapsed acute leukemia (AL) who underwent a second allogeneic hematopoietic stem cell transplantation (alloHSCT). After a median follow-up of 941 days (range, 69-2842 days), leukemia-free survival (LFS) and overall survival (OS) at 3 years were 26.6% and 25.6%, respectively. The nonrelapse mortality rate (NMR) and cumulative incidence of relapse (CIR) were 36.4% and 42.4%, respectively. The Cox regression analysis demonstrated that the risk factors at second transplantation for predicting limited LFS were active disease (hazard ratio (HR) = 5.1), reduced intensity conditioning (RIC) (HR = 5.0), matched unrelated donor (MUD) (HR = 3.4) and performance score <80 (HR = 3.2). Pediatric patients with AL who relapsed after their first alloHSCT may survive with a second alloHSCT. Disease status, conditioning intensity, donor type, and performance score at the second transplantation are the relevant risk factors. A score based on these factors may predict the results of the second transplantation.